Conversation with The Cancer Letter

Conversation with The Cancer Letter

NCTN group chairs, experts: Diverse representation of minorities in clinical trials and drug development saves lives
Conversation with The Cancer LetterFreeHealth Equity

NCTN group chairs, experts: Diverse representation of minorities in clinical trials and drug development saves lives

Drug manufacturers and researchers have a moral obligation to design clinical trials that adequately represent the target population for the investigational agent—and these medical products need to be safe and effective for everyone, leading clinical trial experts in oncology say.
By Matthew Bin Han Ong
Danny Milner: mRNA vaccines may become a viable treatment for cancer because of COVID-19 pandemic
Conversation with The Cancer Letter

Danny Milner: mRNA vaccines may become a viable treatment for cancer because of COVID-19 pandemic

The pandemic has accelerated the development of mRNA vaccines, which could have significant implications for cancer research, said Danny Milner, chief medical officer of the American Society for Clinical Pathology, and adjunct associate professor of immunology and infectious diseases in the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health.
By Alice Tracey
In Grothey case, NIH gets failing grades on follow-up, transparency, internal compliance
Conversation with The Cancer LetterFree

In Grothey case, NIH gets failing grades on follow-up, transparency, internal compliance
Miller, Holman discuss NIH’s response to congressional inquiry on sexual misconduct

NIH may be “constrained” in investigating sexual misconduct at NIH-funded institutions once alleged perpetrators are no longer affiliated with these institutions, NIH officials implied in their response to a congressional inquiry on sexual misconduct (The Cancer Letter, Sept. 24, 2021).
By Matthew Bin Han Ong